SODIUM POLYSTYRENE SULFONATE powder, for suspension (2024)

Table of Contents
View Package Photos Drug Label Info Safety Related Resources More Info For This Drug Drug Label Information 2.1 General Information 2.2 Recommended Dosage 2.3 Preparation and Administration 5.1 Intestinal Necrosis 5.2 Electrolyte Disturbances 5.3 Fluid Overload in Patients Sensitive to High SodiumIntake 5.4 Risk of Aspiration 5.5 Binding to Other Orally Administered Medications 7.1 General Interactions 7.2 Cation-Donating Antacids 7.3 Sorbitol 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 2.1 General Information 2.2 Recommended Dosage 2.3 Preparation and Administration 5.1 Intestinal Necrosis 5.2 Electrolyte Disturbances 5.3 Fluid Overload in Patients Sensitive to High SodiumIntake 5.4 Risk of Aspiration 5.5 Binding to Other Orally Administered Medications 7.1 General Interactions 7.2 Cation-Donating Antacids 7.3 Sorbitol 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Find additional resources Safety Related Resources More Info on this Drug View Labeling Archives for this drug SODIUM POLYSTYRENE SULFONATE powder, for suspension RxNorm SODIUM POLYSTYRENE SULFONATE powder, for suspension Get Label RSS Feed for this Drug SODIUM POLYSTYRENE SULFONATE powder, for suspension NDC Codes SODIUM POLYSTYRENE SULFONATE powder, for suspension FAQs
  • Label RSS
  • NDC Code(s): 46287-012-16
  • Packager: CMP Pharma, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated February 1, 2021

If you are a consumer or patient please visit this version.

  • Download DRUG LABEL INFO: PDF XML
  • Official Label (Printer Friendly)

View All Sections

  • HIGHLIGHTS OF PRESCRIBING INFORMATION

    These highlights do not include all the information needed to use SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION safely and effectively. See full prescribing information for SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION, for oral or rectal use
    Initial U.S. Approval: 1958

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a potassium binder indicated for the treatment of hyperkalemia (1).

    Limitation of Use:

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be used an emergency treatment for life threatening hyperkalemia because of its delayed onset of action (1).

    Oral: The average total daily adult dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily (2.1).

    Rectal: The average adult dose is 30 g to 50 g every six hours (2.1).

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is available as a light brown to brown, finely ground powder (3)

    • Hypersensitivity to polystyrene sulfonate resins(4)
    • Obstructive bowel disease (4)
    • Neonates with reduced gut motility(4)
    • Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported (5.1).
    • Electrolyte Disturbances: Severe hypokalemia can occur. (5.2).
    • Fluid overload in patient sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload. (5.3).
    • Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. (5.4).

    Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting (6).


    To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    • Take other orally administered drugs at least 3 hours before or 3 hours after SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION (7.1).
    • Cation-Donating Antacids: may reduce the resin's potassium exchange capability and increase risk of systemic alkalosis(7.2).
    • Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended (7.3).

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 11/2017

  • Table of Contents

    2.1 General Information

    2.2 Recommended Dosage

    2.3 Preparation and Administration

    5.1 Intestinal Necrosis

    5.2 Electrolyte Disturbances

    5.3 Fluid Overload in Patients Sensitive to High SodiumIntake

    5.4 Risk of Aspiration

    5.5 Binding to Other Orally Administered Medications

    7.1 General Interactions

    7.2 Cation-Donating Antacids

    7.3 Sorbitol

    8.1 Pregnancy

    8.2 Lactation

    8.4 Pediatric Use

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    *
    Sections or subsections omitted from the full prescribing information are not listed.
  • 1 INDICATIONS AND USAGE

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is indicated for the treatment of hyperkalemia.

    Limitation of Use:

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2)].

  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Information

    Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [see Warnings and Precautions (5.5) and Drug Interaction (7)]

    2.2 Recommended Dosage

    The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

    Oral

    The average total daily adult dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.

    Rectal

    The average adult dose is 30 g to 50 g every six hours.

    2.3 Preparation and Administration

    Prepare suspension fresh and use within 24 hours.

    Do not heat SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION as it could alter the exchange properties of the resin.

    One level teaspoon contains approximately 3.5 g of SODIUM POLYSTYRENE

    SULFONATE FOR SUSPENSION and 15 mEq of sodium.

    Oral Suspension

    Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [see Warnings and Precautions (5.4)].

    Enema

    After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.

    Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.

    Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.

  • 3 DOSAGE FORMS AND STRENGTHS

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a light brown to brown, finely ground powder and is available in 454 g jars.

  • 4 CONTRAINDICATIONS

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is contraindicated in patients with the following conditions:

    • Hypersensitivity to polystyrene sulfonate resins
    • Obstructive bowel disease
    • Neonates with reduced gut motility
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Intestinal Necrosis

    Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.

    • Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
    • Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.

    5.2 Electrolyte Disturbances

    Monitor serum potassium during therapy because severe hypokalemia may occur.

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION.

    5.3 Fluid Overload in Patients Sensitive to High SodiumIntake

    Each 15 g dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload.

    Adjustment of other sources of sodium may be required.

    5.4 Risk of Aspiration

    Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION with the patient in an upright position.

    5.5 Binding to Other Orally Administered Medications

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Patients with gastroparesis may require a 6 hour separation. [see Dosage and Administration (2.1) and Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed elsewhere in the labeling:

    • Intestinal Necrosis [see Warnings and Precautions (5.1)]
    • Electrolyte Disturbances [see Warnings and Precautions (5.2, 5.3)]
    • Aspiration [see Warnings and Precautions (5.4)]

    The following adverse reactions have been identified during post-approval use of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

    Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)
    Metabolic: systemic alkalosis

  • 7 DRUG INTERACTIONS

    7.1 General Interactions

    No formal drug interaction studies have been conducted in humans.

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION has the potential to bind other drugs. In in vitro binding studies, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Binding of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is administered. Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.

    7.2 Cation-Donating Antacids

    The simultaneous oral administration of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis.

    7.3 Sorbitol

    Sorbitol may contribute to the risk of intestinal necrosis [see Warnings and Precautions (5.1)] and concomitant use is not recommended.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

    8.2 Lactation

    Risk Summary

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.

    8.4 Pediatric Use

    Studies of safety and efficacy have not been conducted in pediatric patients.

    In pediatric patients, as in adults, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.

    In neonates, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION use [see Warnings and Precautions (5.4)].

  • 10 OVERDOSAGE

    Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

  • 11 DESCRIPTION

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:

    SODIUM POLYSTYRENE SULFONATE powder, for suspension (2)

    The drug is a light brown to brown, finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.

    One gram of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION contains 4.1 mEq of sodium.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a non-absorbed, cation exchange polymer that contains a sodium counterion.

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.

    As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.

    12.2 Pharmacodynamics

    The effective lowering of serum potassium with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION may take hours to days.

    12.3 Pharmacokinetics

    The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically.

    Drug Interactions

    In vitro binding studies showed that SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION bound significantly to the following tested drugs – warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies have not been performed.

  • 16 HOW SUPPLIED/STORAGE ANDHANDLING

    SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is available as a light brown to brown, finely ground powder in jars of 1 pound (454 g), NDC 46287-012-16.

    Store at 20° - 25° C (68° - 77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]

  • 17 PATIENT COUNSELINGINFORMATION

    Drug Interactions

    Advise patients who are taking other oral medication to separate the dosing of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION by at least 3 hours (before or after) [see Dosage and Administration (2.1), Warnings and Precautions (5.5), and Drug Interactions (7.1)]

  • SPL UNCLASSIFIED SECTION

    Rx Only

    Manufactured by:
    CMP Pharma, Inc.
    Farmville, NC 27828
    Copyright©2017. CMP Pharma Inc. All rights reserved.

    3018
    Revised 11/2017

  • PRINCIPAL DISPLAY PANEL - 454 g Jar Label

    NDC 46287-012-16
    454 g

    Sodium Polystyrene
    Sulfonate for Suspension

    USUAL DOSAGE: 15 g (approximately 4 level teaspoonfuls)
    one to four times daily in water. For rectal use, see complete
    instructions in package insert The effect must be carefully
    controlled by frequent serum potassium determinations
    within each 24 hour period Sodium content approximately
    60 mEq per 15 g.

    SEE PACKAGE INSERT FOR COMPLETE INSTRUCTIONS.

    Suspension should be freshly prepared and not stored beyond
    24 hours.

    Dispense in a tight, light resistant container.

    Store at 20°-25°C (68°-77°F); excursions permitted to
    15°-30°C (59°-86°F). [See USP Controlled Room
    Temperature].
    GTIN: 00346287012160

    Rx Only

    3047
    R1017

    PHARMA
    Farmville, NC 27828

    SODIUM POLYSTYRENE SULFONATE powder, for suspension (3)

  • INGREDIENTS AND APPEARANCE
    SODIUM POLYSTYRENE SULFONATE
    sodium polystyrene sulfonate powder, for suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:46287-012
    Route of AdministrationORAL, RECTAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z) (POLYSTYRENE SULFONIC ACID - UNII:70KO0R01RY) SODIUM POLYSTYRENE SULFONATE1g in1g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:46287-012-16454 g in 1 JAR; Type 0: Not a Combination Product01/19/1989
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA08991001/19/1989

    Labeler -CMP Pharma, Inc.(005224175)

    Establishment
    NameAddressID/FEIBusiness Operations
    CMP Pharma, Inc.005224175MANUFACTURE(46287-012) , PACK(46287-012) , LABEL(46287-012) , ANALYSIS(46287-012)

View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!

View Labeling Archives for this drug

SODIUM POLYSTYRENE SULFONATE powder, for suspension

Number of versions: 6

Published Date (What is this?) Version Files
Feb 2, 2021 6 (current) download
Dec 24, 2020 5 download
Mar 9, 2018 4 download
Mar 7, 2017 3 download
Oct 16, 2012 2 download
Sep 5, 2012 1 download

RxNorm

SODIUM POLYSTYRENE SULFONATE powder, for suspension

RxCUI RxNorm NAME RxTTY
1 2101899 sodium polystyrene sulfonate 15 GM Powder for Suspension PSN
2 2101899 sodium polystyrene sulfonate 15000 MG Powder for Oral Suspension SCD
3 2101899 sodium polystyrene sulfonate 15 to 60 GM Powder for Oral Suspension SY
4 2101899 sodium polystyrene sulfonate 30 to 50 GM Powder for Rectal Suspension SY
5 2101899 sodium polystyrene sulfonate 4.1 MEQ in 1 GM Powder for Oral Suspension SY

Get Label RSS Feed for this Drug

SODIUM POLYSTYRENE SULFONATE powder, for suspension

To receive this label RSS feed

Copy the URL below and paste it into your RSS Reader application.

https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=2017bfbe-cda8-46f1-b4f1-9c086c3249a9

To receive all DailyMed Updates for the last seven days

Copy the URL below and paste it into your RSS Reader application.

https://dailymed.nlm.nih.gov/dailymed/rss.cfm

What will I get with the DailyMed RSS feed?

DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.

DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.

How to discontinue the RSS feed

If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.

Why is DailyMed no longer displaying pill images on the Search Results and Drug Info pages?


Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels.

We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.

NDC Codes

SODIUM POLYSTYRENE SULFONATE powder, for suspension

If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such.

NDC
1 46287-012-16
SODIUM POLYSTYRENE SULFONATE powder, for suspension (2024)

FAQs

What is sodium polystyrene sulfonate suspension used for? ›

Sodium polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Powder for Suspension.

How to administer sodium polystyrene sulfonate suspension? ›

Mix the powder with 3 to 4 milliliters (mL) of water or syrup. Each dose of the powder must be mixed with a liquid right before you take it. Stir the powder mixture to dissolve the medicine. Do not store the liquid mixture to take later.

When is the best time to take sodium polystyrene sulfonate? ›

Sodium polystyrene sulfonate is given as a rectal enema. Use this medicine at least 3 hours before or after taking oral medicines. If your stomach takes too long to empty food (gastroparesis), use this medicine 6 hours before or after taking oral medicines.

How long does it take for sodium polystyrene to work? ›

Since the effective lowering of serum potassium with sodium polystyrene sulfonate may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia associated with states of rapid tissue breakdown (e.g., burns and renal failure) or hyperkalemia so marked as to constitute ...

What foods should you avoid when taking sodium polystyrene sulfonate? ›

Sodium Polystyrene Sulfonate Food

Foods high in potassium such as orange juice and other fruit juices may reduce the effectiveness of sodium polystyrene sulfonate in treating your condition. Do not mix sodium polystyrene sulfonate in fruit juice or drink fruit juice with it.

What are the side effects of sulfonate? ›

Check with your doctor right away if you have confusion, dry mouth, increased thirst, irregular heartbeat, irritability, muscle cramps, nausea or vomiting, or trouble breathing. This medicine may cause a serious stomach or bowel problem, called intestinal necrosis.

How much water do you need for sodium polystyrene sulfonate powder? ›

If you are taking sodium polystyrene sulfonate powder by mouth, mix the powder with 20 to 100 mL (about 1 to 3 ounces) of water or syrup as directed by your doctor. Measure carefully, using level teaspoonfuls of the powder. Use the mixture shortly after preparation; do not store beyond 24 hours.

Is sodium polystyrene sulfonate safe? ›

Sodium polystyrene sulfonate (SPS) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

What are the side effects of SPS 15gm 60ml suspension? ›

Loss of appetite, nausea, vomiting, or constipation may occur. Diarrhea may occur less often. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Which drug should not be given with sodium polystyrene sulfonate? ›

These medicines were the blood pressure medicines amlodipine and metoprolol, the antibiotic amoxicillin, the water pill furosemide, the seizure medicine phenytoin, Page 2 and the blood-thinner warfarin. The study found significant binding to sodium polystyrene sulfonate occurred with all of these medicines.

Does polystyrene sulfonate cause constipation? ›

This medication may cause serious (rarely fatal) intestinal problems (such as bleeding, blockage). Get medical help right away if any of these very serious side effects occur: severe constipation, bloating/swelling/pain in the stomach/abdomen, black/bloody stools, vomit that looks like coffee grounds.

What should I check before giving sodium polystyrene sulfonate? ›

What should I discuss with my healthcare provider before using sodium polystyrene sulfonate? You should not use sodium polystyrene sulfonate if you are allergic to it, or if you have: low potassium levels (hypokalemia); or. a bowel obstruction.

How do you take sodium polystyrene sulfonate suspension? ›

Take this medication by mouth, or use it rectally as directed by your doctor. If you are taking this medication by mouth, take it as directed by your doctor, usually 1 to 4 times a day. Carefully measure the dose using a special measuring device/spoon, or use the prescribed number of pre-measured bottles of suspension.

Which condition is treated with sodium polystyrene sulfonate? ›

Sodium polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia.

Does sodium polystyrene sulfonate remove potassium from the body? ›

This medication is used to treat a high level of potassium in your blood. Too much potassium in your blood can sometimes cause heart rhythm problems. Sodium polystyrene sulfonate works by helping your body get rid of extra potassium.

Is sodium polystyrene sulfonate good for hair? ›

For hair styling, the film-forming Sodium Polystyrene Sulfonate is truly multifunctional. In styling aids, such as lotions, spritzes, mousses, and waxes, it provides flexible styling and manageability without a stiff hold. It covers hair with a flexible film, fixing the style in place, and easing combing and brushing.

What is the purpose of polystyrene sulfonate retention enema? ›

This medication is used to treat a high level of potassium in your blood. Too much potassium in your blood can sometimes cause heart rhythm problems. Sodium polystyrene sulfonate works by helping your body get rid of extra potassium.

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Aracelis Kilback

Last Updated:

Views: 6073

Rating: 4.3 / 5 (64 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Aracelis Kilback

Birthday: 1994-11-22

Address: Apt. 895 30151 Green Plain, Lake Mariela, RI 98141

Phone: +5992291857476

Job: Legal Officer

Hobby: LARPing, role-playing games, Slacklining, Reading, Inline skating, Brazilian jiu-jitsu, Dance

Introduction: My name is Aracelis Kilback, I am a nice, gentle, agreeable, joyous, attractive, combative, gifted person who loves writing and wants to share my knowledge and understanding with you.